Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5447926 | BAUSCH AND LOMB | Quinolone carboxylic acid derivatives |
Apr, 2016
(8 years ago) | |
US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6699492 | BAUSCH AND LOMB | Quinolone carboxylic acid compositions and related methods of treatment |
Mar, 2019
(5 years ago) | |
US6685958 | BAUSCH AND LOMB | Quinolone carboxylic acid compositions and related methods of treatment |
Jun, 2021
(2 years ago) | |
US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(5 years from now) | |
US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(5 years from now) | |
US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(6 years from now) |
Besivance is owned by Bausch And Lomb.
Besivance contains Besifloxacin Hydrochloride.
Besivance has a total of 7 drug patents out of which 3 drug patents have expired.
Expired drug patents of Besivance are:
Besivance was authorised for market use on 28 May, 2009.
Besivance is available in suspension/drops;ophthalmic dosage forms.
Besivance can be used as method of treating ocular bacterial infections.
Drug patent challenges can be filed against Besivance from 28 May, 2013.
The generics of Besivance are possible to be released after 09 January, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC